The article will discuss GPCR targets and noteworthy pipelines from Roche and TEVA at JPM Healthcare 2024.

This article summarizes GPCR targets and pipelines highlighted by AstraZeneca, Pfizer, and Eli Lilly at JP Morgan Healthcare Conference 2024.

This article will introduce the GPCR targets and pipelines that received attention at the JP Morgan Healthcare Conference 2024.

TAR-210 is an intravesical drug delivery system that is designed to provide local, continuous release of erdafitinib.

On Jan 25, 2024, the 2024 ASCO_GU reported results from suspending enzalutamide combo tx in high-risk BCR prostate cancer men.

Hospitalization data for darolutamide/docetaxel in metastatic prostate cancer were presented at 2024 ASCO_GU on Jan 25, comparing daro/docetaxel/ADT with placebo/docetaxel/ADT.

On Jan 25, 2024, new data comparing subcutaneous (SC) versus intravenous (IV) nivolumab in pre-treated advanced/metastatic ccRCC was unveiled at ASCO_GU 2024.

APL-1202 (nitroxoline) is a reversible and orally available MetAP2 inhibitor with anti-angiogenic and anti-tumor activities.

On Jan 25, 2024, the 2024 ASCO_GU summarized a phase III trial on first-time bladder cancer patients treated with neoadjuvant intravesical MMC.

2024 ASCO_GU presented new trial data on infigratinib, an FGFR3 inhibitor, showing promise in clinical use.

The latest ASCO_GU 2024 update summarized new clinical findings on disitamab vedotin and toripalimab as an innovative neoadjuvant therapy for HER2+ advanced local MIBC patients.

Datopotamab deruxtecan (Dato-DXd) is an ADC comprising a humanized anti-TROP2 IgG1 monoclonal antibody bonded to a potent topoisomerase I inhibitor through a stable, tumor-specific, cleavable tetrapeptide linker.